Apatinib Plus Gefitinib As First-Line Treatment in Advanced EGFR-Mutant NSCLC: the Phase III ACTIVE Study (CTONG1706).
Journal of Thoracic Oncology（2021）
关键词
Non-small cell lung cancer,Epidermal growth factor receptor,Vascular endothelial growth factor,Tar-geted therapy,Apatinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要